Definitive Contract 75N93018C00041
Award Date 8/8/18
Potential Completion Date 2/14/20
Potential Value $520K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Doylestown, PA 18901, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
- This federal contract award was made by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Creare LLC, doing business as Creare, a small business engineering research and development company. The $591,870.00 Small Business Innovation Research (SBIR) Phase I contract is for the development of an optimized dry powder formulation and delivery system for the anti-tuberculosis drug clofazimine. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
- <p>This is a $225,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Windtree Therapeutics, Inc. under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development of a "K4L SURFACTANT AEROSOL TO REDUCE INFLUENZA LUNG INJURY" and has an ultimate completion date of December 31, 2016. The contract is designated as a Total Small Business set-aside.</p>
- <p>The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Purchase Order contract to SM Biochemicals LLC, a Minority Owned, For Profit, Limited Liability Company that manufactures goods. The contract, valued at $19,090.00, is for the delivery of CHEMICAL QVD-OPH and has a completion date of May 31, 2019. The contract was set aside for small businesses.</p>
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase II contract to Luna Innovations Incorporated, a manufacturer of goods, for the development of "Innovative Oral Formulations for Anti-TB Drugs". The firm-fixed-price contract, with a potential value of $1,499,796.00, was awarded on August 28, 2018, and is set to be completed by November 30, 2020. As a...
- This is a Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Metallopharm LLC, a small disadvantaged business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $224,868.00, is for the development of a formulation for the oral delivery of the antibiotic Capreomycin. The contract has a firm fixed price pricing type and a total small...
- Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
- This is a purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the National Institute For Research In Tuberculosis, a non-profit organization that operates as a hospital. The $537,500.00 firm fixed price award is to provide support to conduct studies on tuberculosis in India. The contract has a performance period ending on May 31, 2019 and was awarded on November 30, 2015. No set-aside was used for this contract. The National...
- This federal contract award, with ID HHSN272201000037C, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Coordinated Program Development LLC, a small business. The contract, valued at $248,901.00, is for the development of oral aminoglycoside-cochleate formulations, as part of the Small Business Innovation Research (SBIR) program Phase I. The contract is a definitive, firm-fixed-price contract with a completion date of September 14, 2011.